Pharma Queries
Dr. Brian W Tempest
www.briantempest.com
Beximco
May 14 2014
Hale & Tempest
Dr Brian Tempest advises Companies, Banks, High Net Worth Individuals and Investment Funds on
their Strategy in the Emerging World based on his wide experience in China, Japan, South East Asia
and India where he has lived for the last decade.
Brian has worked for Ranbaxy Laboratories since 1995 holding the position of Managing Director
and Chief Executive Officer until 2005. He was then Chief Mentor and Non Executive Director until
2008 when he retired. He is one of the few westerners to have led a Sensex Nifty 50 Indian blue Chip
MNC and as a result has a valuable insight into India. Brian has also worked for Glaxo as Regional
Director Far East and Regional Director Middle East & Africa from 1985 to 1992.
Brian has worked in the Pharmaceutical Industry for the last 41 years and has managed Healthcare
businesses in North America, South America, Europe, Africa, Middle East, Australasia, China, Japan
and India. He has also led many sessions at Investor Meetings held around the world.
He is now Independent Chairman of Religare Capital Markets PLC , a Non Executive Director of
Fortis Healthcare the leading Asian Healthcare Company, a Non Executive Director of SRL the
largest Indian Diagnostic Company and a Non Executive Director of Glenmark Pharmaceuticals. He
is a member of the SCRIP Global awards panel and is on the Editorial Board of the Journal of
Generic Medicines. Brian speaks at global conferences and more information on these presentations
can be found on his website www.briantempest.com.
Brian has a PhD in Polymer Chemistry from Lancaster University in 1971 and in 2009 he became
Chairman of the Advisory Board for the Lancaster University Management School, UK. He is a
Fellow of the Royal Society of Medicine and a Fellow of the Royal Society of Chemistry and is a
Chartered Chemist. He is now Chairman and Senior Partner of Hale & Tempest Co Ltd
Hale & Tempest
Nigeria, South Africa & Angola
source: Economist 12 April 2014
Hale & Tempest
Factories in Africa
source: BWT Research 2013
Hale & Tempest
Evans Medical, Nigeria
source: BWT
Mr Olubunmi Olaopa started his career in the industry with Glaxo Nigeria
Plc and rose to become the Managing Director of Glaxo Wellcome Nigeria
Ltd in 1996. Later when Glaxo Wellcome was merged with SmithKline
Beecham Plc in 2000, he was appointed the Managing Director,
GlaxoSmithKline (Pharmaceutical) Nigeria & West Africa. He was the
Managing Director Cipla Evans Nigeria Ltd before his present appointment
as the Group Managing Director of Evans Medical Nigeria Limited.
Professor Elebute (ex Chairman Evans Medical)
15 Maduagwu-Koronu Street
Surulere
PO Box 8968
LAGOS
NIGERIA
Hale & Tempest
Angola Market Size
source: BWT Research 2014
Overall it is estimated from business contacts that the total
size of the Angolan Pharma market is $500m including
government tenders. This is estimated to be comprised of
a private trade segment of $300m. In addition there is
estimated to be a $100m tender market which probably
contains many HIV and Malaria medicines. The final
$100m is estimated to be the supplies to the private mines
and oil fields
Hale & Tempest
French West Africa Markets
source: IMS 2010
EUR
EUR
EUR
EUR
CMA/2009/07 CMA/2010/07 CUF/2009/07 CUF/2010/07
(Milliers)
(Milliers)
(Milliers)
(Milliers)
Marché sélectionné
43,247
49,040
25,411
29,140
COTE D IVOIRE
11,962
14,032
7,219
8,554
CAMEROUN
6,314
7,051
3,776
4,266
SENEGAL
6,820
7,043
3,715
4,005
MALI
3,475
4,362
1,961
2,445
CONGO
3,697
4,063
2,273
2,401
GABON
3,914
4,042
2,331
2,363
BENIN
2,452
3,088
1,426
1,931
TOGO
1,964
2,203
1,148
1,342
BURKINA FASO
1,915
2,277
1,066
1,323
734
879
496
509
GUINEE
Hale & Tempest
CROs Jordan
source: BWT Research 2010
Triumpharma was founded in 2002 with a paid up capital of JD0.1m and currently
employs 38 people. The company is now a leading full service regional contract
research organisation offering services covering all aspects related to clinical
research including phase1,2,3 and 4 clinical trials. The Company has 100 beds and 4
mass spectrometer-HPLC instruments. It is certified by AFSSAPS (2009), USA FDA
(2008) and has GMP, GLP and GCP approvals. The clinical trial business is generating
a positive cash flow which is partly being invested in a drug delivery development
programme where some international patents are now been filed. The greatest
obstacle to setting up this business was in the initial funding
International Pharmaceutical research Centre (IPRC) was founded in 1994 as a private
company with a paid up capital of JD 0.1m and currently employs 100 people. IPRC is a
leading full service regional Contract Research Organisation offering service covering
most aspects of clinical research. It is certified by the UK MHRA and employs 100
people. Sales reached JD 2.6m in 2008 of which exports are 60%.
These successful Clinical Research Organisations are adding to the positive
reputation of the Jordanian Healthcare sector and improving the rigor of the technical
climate within Jordan. Novartis, Sanofi Aventis and Organon from the big pharma
industries have used Jordanian CROs
Hale & Tempest
CPhI Russia 137 Companies
Source: 17 April 2014
•China 67
•Russia 21
•India 12
•Italy 7
•Czech Republic 5
•Poland, Germany, South Korea 4
•Indonesia, Pakistan, Romania, Latvia, Slovakia,
Morocco, Jordan, Spain, Greece, France, Ukraine Hale & Tempest
Switzerland, Malaysia 1
[email protected]
www.briantempest.com
Hale & Tempest
Download

Pharma Queries - Dr. Brian W. Tempest